Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol 2025 Sep 8:S1470-2045(25)00480.
PMID: 40934933